Oral Drug Imlunestrant Under Investigation: Degrades Estrogen Receptors and Penetrates the Brain

A new investigational drug, imlunestrant, is currently under development as a potential treatment option. Researchers are studying imlunestrant, an oral medication, for its ability to selectively degrade estrogen receptors and penetrate the brain. Specifically, scientists designed imlunestrant to target and break down estrogen receptors within the body. The drug is administered orally, and early research indicates it can cross the blood-brain barrier, allowing it to reach the brain. The drug’s mechanism of action involves selectively degrading estrogen receptors, which are proteins that play a role in various biological processes.

Newsflash | Powered by GeneOnline AI
Date: April 14, 2025

Related posts:

Illumina launches its first product enabling long- and short-read sequencing on one instrument Research: Drug Pricing Models Key to Pharma Success; Value Demonstration is Crucial Beyond Patent Expiration Report: Strategic Patent Extensions Could Add Billions to Pharmaceutical Revenue EU Issues New Guidelines to Fortify Radiopharmaceutical Supply Chain Amid Rising Demand for Cancer Treatments

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後